Arrowhead, Takeda: Topline Results from Phase 2 Study in Liver Disease

  Fibrosis regression observed in 50% of patients receiving fazirsiran

− Median reductions of 94% of Z-AAT accumulation in the liver and mean reduction of 68% in histologic globule burden

− Treatment emergent adverse events were generally well balanced between fazirsiran and placebo groups

− Results consistent with AROAAT-2002 open-label study previously published in The New England Journal of Medicine

− Arrowhead to host webcast investor call today, January 9, 2023, at 8:30 a.m. ET

Arrowhead will host a webcast call for investors today, January 9, 2023, at 8:30 a.m. ET to review the Phase 2 data. To register for the webcast, visit the Events and Presentations page under the Investors section of www.arrowheadpharma.com.

https://www.biospace.com/article/releases/arrowhead-and-takeda-announce-topline-results-from-sequoia-phase-2-study-of-fazirsiran-in-patients-with-alpha-1-antitrypsin-deficiency-associated-liver-disease/